The major treatments for MS focus on CD4+ T cells regulation; however, the impact of CD8+ T cells and B-cells reveals that they also play an important role in the disease inflammatory process and progression (Lassmann and van Horssen, 2011), suggesting that the pathogenic response of each patient is critical for determining an optimal treatment approach (Lehmann-Horn et al., 2013). The gene discussed is CD4; the disease is myeloid sarcoma.